Webinar
Integrated Evidence Generation: From planning to practice
September 11, 2024
In areas like rare diseases, planning how to obtain evidence is crucial. This involves bringing non-traditional methodologies into the evidence generation process to demonstrate value to payers, patients, and healthcare providers.
Understanding this approach through tested models helps accelerate the registration pathway, bringing solutions for unmet needs to clinical practice.
This webinar will discuss:
The Importance of Early Access Planning
- Risks and impacts of neglecting access considerations
- Effects on patient reach, pricing, and time-to-market
Understanding Payer Perspectives
- Evidence requirements for payers
- Specific considerations for rare diseases
- Payer viewpoints on cell and gene therapies
Incorporating Access into Drug Development Timelines
- Key milestones and integration strategies
- Case studies of successful implementation
Enabling evidence at scale
- Innovative frameworks and infrastructure for stakeholder needs
- Integrated evidence platforming across product lifecycle
- Real-world case studies and best practices for scalable evidence generation
Alex Gee
Senior Director, Market Access
Alex has 25 years of pharmaceutical industry experience, including 10 years in consulting. He specializes in global pricing and market access projects, ranging from early-phase rare diseases to generic defense for blockbuster brands. With a degree in Genetics and early career experience in the NHS, Alex brings a unique blend of scientific and business acumen to his role. His expertise spans value message development, market research, payer evidence planning, commercialization, and market access submissions. Alex collaborates across various Parexel functional groups to address client challenges, working with payers, KOLs, and HCPs in diverse therapeutic areas, particularly oncology and CNS.
Shruti MP
Director, RWD Solutions
Shruti has over 16 years’ of clinical research experience in real world data (RWD) solutioning, medical writing, product strategy and medical communications, at Parexel and at GlaxoSmithKline. She has broad experience in the development and implementation of scientific data-enabled solutions in clinical trials and RWE studies, across the product development lifecycle. In her current role, Shruti leads operational delivery of studies with novel approaches using RWD and related technologies, while advising on recommended strategies for expanded access to scientific data. She holds a MSc in Biochemistry from Bangalore University, India.